Please assess the completion status of the following clinical trial:

Trial Title: Effectiveness and Acceptability of Stellate Ganglion Block for Posttraumatic Stress Disorder Symptoms - Effectiveness

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Member of the Army on active duty status~* Personal access to Internet~* Anticipated stable assignment to installation for at least 2 months~* Stable dosing for ≥3 months, if receiving psychotropic medications~* Prior to enrollment, offered PTSD treatment using A-level modality (as defined by U.S. Army Medical Command (MEDCOM) policy 14-094; 18 Dec 2014).~* PTSD Checklist - Civilian (PCL-C) score of 32 or greater at screening~* Acceptable clinically indicated preoperative laboratory studies, per standard site-specific protocols~Exclusion Criteria:~* Prior Stellate Ganglion Block (SGB)~* Allergy to amide local anesthetics (e.g., ropivacaine, bupivacaine)~* Pregnancy (evaluated by urine test pre-procedure)~* Current anticoagulant use~* History of a bleeding disorder~* Infection or mass at injection site~* Myocardial infarction within 6 months of procedure~* Phrenic or laryngeal nerve palsy (hoarseness)~* History of glaucoma~* History of schizophrenia, other psychotic disorder, bipolar disorder, or personality disorder (axis 2)~* Moderate or severe traumatic brain injury~* Symptoms of moderate to severe substance use disorder in past 30 days~* Suicidal ideation in the past 2 months, documented by the M.I.N.I.-Plus Suicidality Items~* Any ongoing other major life stressor or condition not listed here that the site Investigator believes clearly would place the participant at risk for injury or a poor outcome

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Stellate Ganglion Block (SGB) (Type: ACTIVE_COMPARATOR): 7-10 mL 0.5% ropivacaine injected under ultrasound visualization ventral to right longus coli muscle (around and into the ventral fascia) and into the longus coli immediately dorsal to the presumed ventral fascia, at the level of the C6 anterior tubercle (landmarks for stellate ganglion).
- Sham Treatment (Type: SHAM_COMPARATOR): 1-2 mL preservative-free normal saline, injected under ultrasound visualization anterolateral to right anterior tubercle of C6.

Based on this trial design, predict the completion outcome and termination type (if applicable).